Patients with different types of cancer respond differently to treatment. The presence of an immune-suppressing protein in non-cancerous immune cells may predict this response. This was shown in a multi-center phase I study using an investigational immune therapy drug. The study, led by a Yale Cancer Center investigator, is described in the Nov. 27 edition of the journal iNature/i. The trial included patients with melanoma or cancers of the lung, kidney, colon, ...
Read More
You have just read an article categorized health
titled Response to New Immunotherapy Drug Predicted by Protein.
Written by:
editor -
Friday, November 28, 2014
There are currently no comments for "Response to New Immunotherapy Drug Predicted by Protein"
Post a Comment